RKLB — Rocket Lab
Real rockets, real backlog, real execution risk. Finally, a proper asymmetry bet.
Rocket Lab started with Electron and has been building toward something much bigger across launch, spacecraft and components. Neutron is the obvious swing factor because it can move the company into a completely different scale of opportunity. This is a real business already. It is also one of the cleaner examples of why asymmetry positions stay small.
Rocket Lab is pretty close to what I actually mean by asymmetry. This is not a tiny company with a PowerPoint and vibes. There is a real launch business, a real space-systems business and a real backlog. There is also enough execution risk that I would be an idiot to size it like Microsoft.
Why I care about this one
The upside is not just “Electron launches more.” The much bigger idea is Rocket Lab becoming a vertically integrated space company. Space systems, Neutron, launch cadence and the strategic moves around them can change the scale of the whole business if management actually executes.
Q2 2026 revenue hit a record $234M, up 62%, and backlog reached $2.36B. Rocket Lab is also pursuing the Iridium acquisition, which could transform the company but raises the stakes around financing, integration and capital allocation.
Q2 2026
Primary sources: Q2 2026 results ↗
Q2 made the operating story larger: record $234M of revenue, $2.36B of backlog and the planned Iridium acquisition all push the vertically integrated space-platform thesis forward. They also push the financing and integration burden forward. The end-2028 execution targets stay unchanged for now.
My position
What I actually bought and sold.
| Date | Type | Account | Dollars | Shares | Price | Return now* |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Buy | Taxable | $4,000 | 47.407 | $84 | -12.4% |
*Return now uses the latest available quote for buys and reinvestments. Sales and fees show “—”.
Valuation & scenario math
The asymmetry sleeve still caps RKLB at 3% of invested assets, and the snapshot was around 1.1%. A neat P/E is not really the useful question here. I care more about whether the 5x path is credible without fantasy assumptions and whether the position stays small enough that being wrong is annoying, not portfolio-changing.
Neutron / backlog / financing milestones
No static price band. I want execution to improve before I increase size: Neutron, backlog conversion, integration and financing quality matter way more than whether the stock is cheaper on a random Tuesday.
This is an execution checkpoint around Neutron, backlog conversion and integration. I am not pretending current earnings are the useful lens. The upside is huge if the platform keeps de-risking. The capital requirements are also huge if it does not.
| Case | What has to be true | Target range | Annualized return from today |
|---|---|---|---|
| Bear | Neutron slips materially, integration consumes capital and the larger platform strategy creates more financing or execution risk than expected. | $35–$55 center ~$45 | -20.0% |
| Base | Neutron enters service, space systems scale, backlog converts and the broader platform strategy is integrated without ugly financing. | $100–$130 center ~$115 | +22.0% |
| Bull | Rocket Lab becomes a much larger integrated launch/space-systems platform and converts today's backlog and acquisitions into durable growth. | $175–$240 center ~$210 | +60.0% |
Returns use the current quote and the time remaining to Dec 31, 2028. The scenario targets stay fixed until the underwriting changes.
Capital allocation
Ambitious enough to be exciting. Ambitious enough to make me nervous.
Launch and space-systems execution, backlog growth and the platform build deserve real credit. Neutron plus multiple acquisitions also make the financing and integration burden much heavier, so the per-share outcome still depends a lot on how management sequences capital.
Stage-relative, not some objective rating-agency grade. The number is there to force the judgment into the open. See the rubric →
What management is actually doing with the cash
This whole thesis is capital allocation. Neutron, acquisitions and vertical integration can create a much bigger company. They can also eat cash at a speed that makes the equity story belong to future shareholders instead of current ones. I want ambition. I just want the financing and sequencing to leave me owning the upside.
What I’m doing with the next dollar
I have enough exposure that I care and enough room that I can add if the execution gets better. A lower stock price is not the same thing as better execution, which feels obvious but is exactly the kind of thing people forget in a drawdown.
What can break this
The risk list is not subtle: Neutron timing, acquisition integration, dilution, launch failures, government contracts and management trying to do too much at once. “Management is ambitious” is genuinely both part of the bull case and part of the bear case here.
Repeated Neutron slippage, deterioration in backlog quality, reckless financing or capital allocation that makes the upside belong mostly to future shareholders would break the thesis.
Rocket Lab is allowed to stay weird and volatile. My job is to make sure the position size does not become equally weird.
The evidence I’m watching
Neutron reaches service on a credible schedule, the Iridium/Mynaric/Motiv integration produces real cross-selling or cost benefits, backlog converts without margins collapsing and the larger platform can be funded without ugly dilution.
Neutron slips materially, acquisition integration burns more cash than expected, backlog quality weakens, launch reliability deteriorates or financing becomes the main thing deciding the per-share outcome.